The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.50
Bid: 3.25
Ask: 3.75
Change: 0.00 (0.00%)
Spread: 0.50 (15.385%)
Open: 3.50
High: 3.50
Low: 3.125
Prev. Close: 3.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genedrive down as plans equity raise despite GBP800,000 tax credit

Fri, 15th Mar 2024 13:50

(Alliance News) - Genedrive PLC shares fell on Friday, after it said it has received a GBP800,000 research and development tax credit.

Shares in the company were down 15% to 3.50 pence each in London on Friday afternoon.

Genedrive said that following the R&D tax credit, its cash balance stands at GBP1.2 million, and it continues to assess its "requirements and a range of funding options that would bridge the gap before revenue generation allows Genedrive to be self-sufficient".

It is planning to raise further equity "in the coming weeks", Genedrive said.

The equity, the company said, will "provide a longer term financing solution for the company's plans which include further driving sales of its two tests in approved markets and also seeking a Food & Drug Administration approval for its AIHL test in the US market which is be expected to be a significant source of future revenues."

"The company expects to be able to announce further details supporting this plan before long," it added.

Genedrive plans to announce its interim results for the six months ended December 31 on March 28.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
28 Jan 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Dec 2019 10:10

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Genedrive Antibiotic Induced Hearing Loss Test Kit Shows High Accuracy

Read more
3 Dec 2019 09:39

Genedrive upbeat on latest results from RNR1 kit testing

(Sharecast News) - Near-patient molecular diagnostics company Genedrive announced on Tuesday that in its case-control clinical validation, the antibiotic-induced hearing loss assay - the 'Genedrive MT-RNR1 ID' kit - achieved a diagnostic sensitivity of 100% and specificity of 100% on a cohort of 303 samples.

Read more
18 Nov 2019 16:00

Genedrive infant hearing loss test gets CE mark

(Sharecast News) - Molecular diagnostics company Genedrive announced on Monday that its antibiotic-induced hearing loss test, the 'Genedrive MT-RNR1 ID' kit, has obtained CE marking.

Read more
18 Nov 2019 11:15

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Genedrive's Antibiotic Induced Hearing Loss Assay Receives CE Marking

Read more
7 Oct 2019 11:59

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

NHS Ethics Approval Granted For Genedrive MT-RNR1 Screening Test Trial

Read more
3 Oct 2019 11:00

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Genedrive Outlook Positive As Revenue Up And Loss Narrows In Full Year

Read more
3 Oct 2019 10:41

Genedrive loss narrowed after double-digit revenue rise

(Sharecast News) - Genedrive on Thursday reported a narrowed annual loss as revenues jumped as its commercial relationship with the US department of defense (DoD) exceeded expectations.

Read more
9 Jul 2019 10:54

Genedrive Revenue To Suffer On Lower Uptake Of Hepatitis Test Kits

(Alliance News) - Shares in Genedrive PLC fell Tuesday after the company warned that it will miss market expectations for 2020 financial year revenue due to slower than expected uptake of the HCV

Read more
28 Mar 2019 10:36

Genedrive Interim Loss Narrows As It Continues Focus On Hepatitis

LONDON (Alliance News) - Genedrive PLC on Thursday reported a reduction in its interim loss, as it continues to progress its hepatitis testing product.For the six months to the end of 2018,

Read more
28 Mar 2019 07:59

Genedrive losses narrow despite increased R&D costs

(Sharecast News) - Molecular diagnostics company Genedrive saw revenues tick ahead slightly in the first half of its financial year but increased research and development costs kept the firm in the red.

Read more
15 Jan 2019 12:44

Genedrive Interim Revenue Rises On US And UK Government Contracts

LONDON (Alliance News) - Genedrive PLC said Tuesday it increased its first-half income and made "good progress" on two UK government funded projects.For the six months to the end

Read more
15 Jan 2019 10:17

Genedrive makes progress with HCV kit in first half

(Sharecast News) - Near-patient molecular diagnostics company Genedrive issued an unaudited update for the six months ended 31 December on Tuesday, reporting revenue of £1.5m, up from £1.3m year-on-year.

Read more
10 Dec 2018 16:23

BGF Investment Management Now Owns 12.8% Stake In Genedrive (ALLISS)

LONDON (Alliance News) - Genedrive PLC said Monday that BGF Investment Management Ltd now owns a 12.8% stake in the company.BGF's stake in the firm prior to Monday's deal, if any,

Read more
29 Nov 2018 13:56

Genedrive To Participate In Study For Use Of HCV Assay In Pharmacies

LONDON (Alliance News) - Genedrive PLC on Thursday said it will participate in an international multicentre trial to assess the impact of out-reach HCV diagnostics and therapy in a pharmacy versus

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.